Signaturefd LLC Has $164,000 Stock Position in Moderna, Inc. $MRNA

Signaturefd LLC lifted its position in Moderna, Inc. (NASDAQ:MRNA) by 20.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,951 shares of the company’s stock after buying an additional 997 shares during the period. Signaturefd LLC’s holdings in Moderna were worth $164,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in MRNA. Bank of New York Mellon Corp increased its holdings in Moderna by 1.8% during the 1st quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company’s stock worth $54,382,000 after purchasing an additional 34,034 shares in the last quarter. Wealthfront Advisers LLC increased its holdings in Moderna by 143.3% during the 1st quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company’s stock worth $879,000 after purchasing an additional 18,268 shares in the last quarter. FORA Capital LLC increased its holdings in Moderna by 31.7% during the 1st quarter. FORA Capital LLC now owns 97,072 shares of the company’s stock worth $2,752,000 after purchasing an additional 23,344 shares in the last quarter. Jump Financial LLC increased its holdings in Moderna by 5,590.0% during the 1st quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock worth $25,584,000 after purchasing an additional 886,567 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Moderna by 12.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock worth $74,557,000 after purchasing an additional 285,662 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on MRNA. Wells Fargo & Company restated an “equal weight” rating on shares of Moderna in a research note on Sunday, July 13th. JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a research note on Friday, August 1st. Cowen began coverage on shares of Moderna in a research note on Sunday, July 13th. They set a “hold” rating for the company. Leerink Partners reduced their price objective on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a research note on Friday, August 22nd. Finally, Barclays reduced their price objective on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a research note on Monday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $41.81.

Moderna Stock Up 0.4%

MRNA stock opened at $28.49 on Friday. The firm has a market cap of $11.08 billion, a price-to-earnings ratio of -3.78 and a beta of 2.01. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $62.11. The company’s fifty day simple moving average is $26.30 and its 200 day simple moving average is $27.41.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.99) by $0.86. The business had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna’s revenue for the quarter was down 41.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. Research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.